# A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

> **NCT03776071** · PHASE3 · COMPLETED · sponsor: **Denovo Biopharma LLC** · enrollment: 260 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Enzastaurin Hydrochloride
- **OTHER:** Placebo
- **DRUG:** Temozolomide
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03776071
- **Lead sponsor:** Denovo Biopharma LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-16
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03776071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03776071, "A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03776071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*